New York, USA, June 01, 2023 (GLOBE NEWSWIRE) -- Cell Therapy Global Market to Grow Rapidly at a CAGR of ~14% by 2028 | DelveInsight
The global cell therapy market is predicted to showcase positive growth owing to the rising incidence of oncological disorders such as blood cancer and others, the increase in cases of critical limb ischemia (CLI), increasing R&D and investments for cell therapy, and growing advances in technologies used for manipulation and administration of cell therapies by leading companies such as Cipla, Bristol-Myers Squibb Company, Johnson & Johnson Services, Novartis AG, Gilead Sciences, and others.
DelveInsight’s Cell Therapy Market Insights report provides the current and forecast market analysis, individual leading cell therapy companies’ market shares, challenges, cell therapy market drivers, barriers, trends, and key market cell therapy companies in the market.
Key Takeaways from the Cell Therapy Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global cell therapy market during the forecast period.
- Notable cell therapy companies such as Cipla, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, Gilead Sciences, Inc., Atara Biotherapeutics, Inc., Takeda Pharmaceutical Company Limited, Tegoscience, Kolon TissueGene, Inc., IMMUSOFT, and several others, are currently operating in the cell therapy market.
- In May 2023, BrightPath Biotherapeutics Co., Ltd., a clinical stage biotechnology company focused on the development of cell therapies derived from invariant natural killer T (iNKT) cells, and Artisan Bio. Inc., a precision genome engineering and drug discovery company, announced that they have signed a research and licensing agreement to accelerate the development of BrightPath’s next-generation iNKT cell therapies.
- In April 2023, Omisirge (omidubicel-onlv), a significantly modified allogeneic cord blood-based cell therapy, was approved by the US Food and Drug Administration to reduce the risk of infection in patients with blood cancer after a myeloablative treatment, such as radiation or chemotherapy.
- In November 2022 AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.
- In October 2022 Century Therapeutics and Bristol Myers Squibb entered into a strategic collaboration to develop iPSC-derived allogeneic cell therapies.
- In April 2022, Kite, a Gilead Company received US FDA approval for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
- In February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the company has received US FDA approval for CARVYKTI™ intended for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
To read more about the latest highlights related to the cell therapy market, get a snapshot of the key highlights entailed in the Global Cell Therapy Market Report
Cell Therapy Overview
Cell therapy is a treatment method that involves replacing diseased or malfunctioning cells with healthy functioning ones. Because of their potential to specialize in specific cells required for healing damaged or malfunctioning tissues or cells, stem cells are mostly used for such sophisticated therapies. Furthermore, cell therapy is used in the development of regenerative medicines, which is a multidisciplinary field aimed at the maintenance, improvement, or restoration of cell, tissue, or organ function using cell therapy-related methods. Cells such as blood and bone marrow cells, mature, immature, and solid tissue cells, adult stem cells, and embryonic stem cells are also commonly employed in cell therapy operations. Furthermore, transplanted cells such as induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are classified as autologous cell therapy and non-autologous cell therapy.
Cell Therapy Market Insights
North America is expected to account for the highest proportion of the cell therapy market in 2023, out of all regions. The cell therapy market is expected to grow significantly in the region due to the importance of key growth factors such as an increasing patient population suffering from cancer, sophisticated healthcare infrastructure, the presence of key players, and among others. The increasing number of product development activities in the region will push the expansion of the cell therapy market even further. For instance, Breyanzi® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, was approved by the US Food and Drug Administration (FDA) in June 2022 for the treatment of adult patients with large B-cell lymphoma (LBCL).
To know more about why North America is leading the market growth in the cell therapy market, get a snapshot of the Cell Therapy Market Outlook
Cell therapy is increasingly being used to treat blood malignancies. For example, Novartis AG’s Kymriah is the first chimeric antigen receptor (CAR) T cell immunotherapy licensed by the US Food and Drug Administration for adult patients with relapsed or refractory follicular lymphoma. The increase in strategic initiatives on cell therapy is also predicted to fuel the cell therapy market. For example, Century Therapeutics and Bristol Myers Squibb announced a strategic collaboration in October 2022 to develop iPSC-derived allogeneic cell treatments.
Similarly, AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. in November 2022, a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that provide a novel cell therapy approach for targeting cancer.
However, challenges associated with cell therapy manufacturing and the extremely high treatment cost of cell therapy may limit the overall cell therapy market growth.
Additionally, the cell therapy market was significantly impacted during the COVID-19 pandemic due to lockdown impositions as a measure to prevent the spread of COVID-19 infection, which resulted in the suspension of cell therapy research and development activities due to a lack of raw materials and required workforce. Nonetheless, the cell therapy market is in a recovery phase as a result of the introduction of COVID-19 vaccines and the resumption of activities in all sectors, including healthcare and pharmaceutical, providing ample opportunities for the cell therapy market to grow at significant revenue during the forecast period.
Get a sneak peek at the cell therapy market dynamics @ Cell Therapy Market Dynamics Analysis
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2020–2028 |
| Base Year | 2022 |
| Cell Therapy Market CAGR | ~14% |
| Key Cell Therapy Companies | Cipla, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, Gilead Sciences, Inc., Atara Biotherapeutics, Inc., Takeda Pharmaceutical Company Limited, Tegoscience, Kolon TissueGene, Inc., IMMUSOFT, among others |
Cell Therapy Market Assessment
- Cell Therapy Market Segmentation
- Cell Therapy Market Segmentation By Type: Autologous And Allogenic
- Cell Therapy Market Segmentation By Cell Type: Stem Cell and Non-Stem Cell
- Cell Therapy Market Segmentation By Indication: Oncological, Cardiovascular, and Others
- Cell Therapy Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the cell therapy market are set to emerge as the trendsetter explore @ Cell Therapy Companies
Table of Contents
| 1 | Report Introduction |
| 2 | Executive summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Key Factors Analysis |
| 5 | Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on Cell Therapy Market |
| 7 | Cell Therapy Market Layout |
| 8 | Global Company Share Analysis – Key 3-5 Companies |
| 9 | Cell Therapy Market Company and Product Profiles |
| 10 | Project Approach |
| 11 | About DelveInsight |
Interested in knowing the cell therapy market by 2028? Click to get a snapshot of the Cell Therapy Market Trends
Related Reports
Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2028 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, among others.
Gene Therapy Competitive Landscape
Gene Therapy Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy companies, including Novartis, Johnson & Johnson, Fibrocell Technologies, Pfizer, HELIXMITH Co., Ltd., Sarepta Therapeutics, REGENXBIO, Solid Biosciences Inc., Lexeo Therapeutics, Spark Therapeutics, Xalud Therapeutics, uniQure, Ultragenyx Pharmaceutical, Nanoscope Therapeutics, among others.
Intratumoral Cancer Therapies Market
Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key intratumoral cancer therapies companies, including Daiichi Sankyo, Amgen, Idera Pharmaceuticals, among others.
Adeno-Associated Virus Vectors in Gene Therapy Market
Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adeno-associated virus vectors in gene therapy companies, including Pfizer, CSL Behring, Spark Therapeutics, Freeline Therapeutics, RegenxBio, Amicus Therapeutics, among others.
Cell and Gene Therapies in Rare Disorders Market
Cell and Gene Therapies in Rare Disorders Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapies in rare disorders companies, including Pfizer, Freeline Therapeutics, Sangamo Therapeutics, 4D Molecular Therapeutics, Spark Therapeutics, Astellas Gene Therapies, Actus Therapeutics, GenSight Biologics, among others.
Gene And Cell Therapies Targeting CNS Disorders Pipeline
Gene And Cell Therapies Targeting CNS Disorders Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene and cell therapies targeting CNS disorders companies, including UniQure Biopharma, Brain Neurotherapy Bio, NeuroGeneration, Eli Lilly and Company, Sio Gene Therapies, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Blogs
Gene Therapy: The Next Milestone in Treating Complex Diseases
Gene Therapy for Duchenne Muscular Dystrophy
Avrobio’s Gene Therapy for Cystinosis Treatment
Emerging Gene Therapy in the Dermatology
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
